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Background: Right-sided metastatic colorectal cancer (mCRC) patients have poor prognosis and achieve limited benefit from
first-line doublets plus a targeted agent. In this unplanned analysis of the TRIBE study, we investigated the prognostic and
predictive impact of primary tumor sidedness in mCRC patients and the differential impact of the intensification of the
chemotherapy in subgroups defined according to both primary tumor sidedness and RAS and BRAFmutational status.
Patients and methods: Patients were randomized to receive upfront 5-fluoruracil, leucovorin, and irinotecan (FOLFIRI) plus
bevacizumab or 5-fluoruracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab. Tumors were defined as
right- or left-sided if they originated from the caecum to the transverse colon or within the splenic flexure and beyond,
respectively. Patients with available information about both primary sidedness and RAS and BRAF status were included in the
present analysis. Progression-free survival (PFS), overall survival (OS) and RECIST response rate were assessed according to tumor
location and RAS and BRAFmutational status.
Results: Information about primary sidedness and RAS and BRAF status was available for 358 (70.5%) out of 508 randomized
patients. Patients with right-sided tumors (N¼ 173) presented shorter OS [23.7 versus 31.0months, HR¼ 1.42 (95% CI 1.09–1.84),
P¼ 0.010] and a trend toward shorter PFS [10.2 versus 11.5months, HR¼ 1.24 (95% CI: 0.98–1.56), P¼ 0.083] than those with
left-sided tumors (N¼ 185), but these associations were no longer evident when adjusting for RAS and BRAF status. Patients with
right-sided tumors achieved more relative benefit from the intensification of the chemotherapy backbone in terms of both PFS
(HR¼ 0.59 versus 0.89, P for interaction¼ 0.099) and OS (HR¼ 0.56 versus 0.99, P for interaction¼ 0.030) and this advantage was
independent of their RAS and BRAF status.
Conclusions: FOLFOXIRI plus bevacizumab may be regarded as a preferred first-line treatment option for clinically selected
patients with right-sided metastatic colorectal cancer irrespective of their RAS and BRAFmutational status. Trial registration:
clinicaltrials.gov identifier NCT00719797.
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Introduction
Recent evidence from clinical trials and translational studies
highlights that biologic, molecular and immunologic differences
between right- and left-sided colorectal cancers translate into sig-
nificant clinical differences, with relevant implications in meta-
static patients’ management [1–5].
A wide amount of data consistently shows that left-sidedness is
associated with better prognosis [6] and meaningful benefit from
anti-EGFR agents [7], thus leading to consider EGFR blockade as a
preferred upfront strategy for RAS and BRAF wild-type patients [8,
9]. On the other hand, right-sidedness predicts poor prognosis and
resistance to anti-EGFRs also in RAS and BRAFwild-type tumors [8,
9], thus pointing out the contribution ofmolecular or environmental
factors other than BRAFmutation to these findings. Limited survival
results are achieved in these patients with first-line doublets plus a
biologic agent, thus highlighting the need to investigate how to coun-
teract the intrinsic aggressiveness of right-sided tumors [8, 9].
The academic phase III TRIBE trial reported significant pro-
gression-free survival (PFS) and OS benefit from the addition of
oxaliplatin to FOLFIRI plus bevacizumab in previously untreated
metastatic colorectal cancer (mCRC) patients [10, 11].
In this unplanned subgroup analysis of the TRIBE study we
investigated whether the effect of the intensification of the up-
front chemotherapy backbone was different according to tumor
sidedness, and whether this potentially heterogeneous effect dif-
fered according to RAS and BRAFmutational status.
Methods
Study design and patients
The TRIBE design, treatments, eligibility and exclusion criteria, and study
procedures have been previously reported [11]. PFS was the primary end
point. The study was approved by Ethics Committees at each participating
center and was conducted in accordance with the Declaration of Helsinki.
All patients provided their written informed consent. Only patients with
available information about both primary sidedness and RAS and BRAF
mutational status are included in the present analysis.
Definition of primary sidedness
Coherently with previous subgroup analyses of other randomized stud-
ies, tumors located in the caecum, ascending and transverse colon were
defined as right-sided, while those located within the splenic flexure and
beyond were defined as left-sided.
Definition of end points
PFS was defined as the time from randomization to the evidence of dis-
ease progression according to RECIST version 1.1, or death, whichever
Table 1. Demographic and baseline characteristics of study population according to primary tumor sidedness and treatment arm
Characteristics Right-sided tumors (N5116) Left-sided tumors (N5 242)
FOLFIRI plus bev
(N544)
FOLFOXIRI plus bev
(N5 72)
FOLFIRI plus bev
(N5 129)
FOLFOXIRI plus bev
(N5113)
Age
Median 61 61 59 59
Range 29–74 31–75 38–75 29–75
Gender, N (%)
Male 31 (71) 45 (63) 67 (52) 75 (66)
Female 13 (29) 27 (37) 62 (48) 38 (34)
ECOG PS, N (%)
0 38 (86) 63 (88) 116 (90) 101 (89)
1–2 6 (14) 9 (12) 13 (10) 12 (11)
Previous adjuvant therapy, N (%)
No 40 (91) 64 (89) 110 (85) 99 (88)
Yes 4 (9) 8 (11) 19 (15) 14 (12)
Time to metastases, N (%)
Synchronous 38 (86) 58 (81) 101 (78) 90 (80)
Metachronous 6 (14) 14 (19) 28 (22) 23 (20)
Sites of metastases, N (%)
Single 7 (16) 25 (35) 34 (26) 35 (31)
Multiple 37 (84) 47 (65) 95 (74) 78 (69)
RAS/BRAF status, N (%)
RAS and BRAF wild-type 9 (20) 16 (22) 52 (40) 47 (42)
RAS mutated 28 (64) 48 (67) 73 (57) 60 (53)
BRAF mutated 7 (16) 8 (11) 4 (3) 6 (5)
ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFIRI, fluorouracil, leucovorin, and irinotecan; FOLFOXIRI, fluorouracil, leucovorin,
oxaliplatin, and irinotecan; bev, bevacizumab.
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occurred first; overall survival (OS) was defined as the time from ran-
domization to death from any cause; overall response rate (ORR) was
defined as the proportion of patients achieving partial or complete re-
sponse according to RECIST version 1.1.
Statistical analysis
Survival functions from time-to-event data were estimated with the
Kaplan–Meier product limit method. The association between primary
sidedness and molecular status with survival parameters and ORR was
assessed with Cox and logistic regression models, respectively, including
ECOGPS, previous adjuvant chemotherapy and treatment arm as covari-
ates. Subgroup analyses were done including an interaction term in the
statistical models.
Results
Study population and baseline characteristics
Information about primary sidedness and RAS and BRAF muta-
tional status were available for 358 (70%) out of 508 patients
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Figure 1. Kaplan–Meier estimates of PFS and OS according to primary sidedness and treatment arm. (A) Progression-free survival and (B)
overall survival. HR, hazard ratio; mos, months; Arm A indicates FOLFIRI plus bevacizumab. Arm B indicates FOLFOXIRI plus bevacizumab.
Annals of Oncology Original article
Volume 29 | Issue 7 | 2018 doi:10.1093/annonc/mdy140 | 1531
randomized in the TRIBE trial. One hundred and seventy-three
(48%) and 185 (52%) patients had right- and left-sided primary
tumors, respectively. Their distribution between treatment
arms was unbalanced, since a higher percentage of patients with
right-sided tumors were allocated to arm B than to arm A (39%
versus 25%, P ¼ 0.006). Baseline characteristics according
to primary sidedness and treatment arm are summarized in
Table 1.
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Figure 2. Kaplan–Meier estimates of PFS and OS according to RAS and BRAF mutational status, primary sidedness and treatment arm. (A)
Progression-free survival in RAS and BRAF wild-type tumors. (B) Progression-free survival in RAS mutant tumors. (C) Progression-free survival in
BRAF mutant tumors. (D) Overall survival in RAS and BRAF wild-type tumors. (E) Overall survival in RAS mutant tumors. (F) Overall survival in
BRAF mutant tumors. HR, hazard ratio; Arm A indicates FOLFIRI plus bevacizumab. Arm B indicates FOLFOXIRI plus bevacizumab.
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One hundred and twenty-four (35%), 209 (58%) and 25 (7%)
patients had RAS and BRAF wild-type, RAS mutated or BRAF
mutated tumors, respectively, with no imbalances between treat-
ment arms (P¼ 0.894). As compared with left-sided tumors,
right-sided ones harbored more frequently RAS (66% versus
55%) and BRAFmutations (13% versus 4%) (P< 0.001).
As compared with patients with left-sided primary tumors,
those with right-sided tumors presented shorter OS [23.7months
versus 31.0months, HR, 1.42 (95% CI 1.09–1.84), P¼ 0.010] and
a trend toward shorter PFS [10.2months versus 11.5months,
HR, 1.24 (95% CI 0.98–1.56), P¼ 0.083]. When adjusting for
mutational status, the impact of primary sidedness on PFS was
not significant [HR, 1.15 (95% CI 0.90–1.47, P¼ 0.252)], while a
trend was retained in terms of OS [HR, 1.30 (95% CI 0.99–1.70),
P¼ 0.061]. No difference was evident in ORR (P¼ 0.937). The
prognostic effect of primary sidedness across different molecular
subgroups is described in Table 2.
Primary tumor sidedness was associated with differential treat-
ment effect in terms of PFS (P for interaction¼ 0.099) and
OS (P for interaction¼ 0 .030), with higher benefit from the in-
tensification of the chemotherapy backbone among patients with
right- than left-sided tumors (Table 2 and Figure 1), while no
differences were evident in ORR (P for interaction¼ 0.942).
When looking at the predictive impact of primary sidedness
according to RAS and BRAF status, no significant interaction
was reported either in terms of PFS (P¼ 0.292), OS (P¼ 0.165)
or ORR (P¼ 0.584). However, a differential treatment effect
favoring right-sided tumors was evident in PFS and OS in all
molecular subgroups (Table 2 and Figure 2).
Results about the prognostic and predictive role of RAS and
BRAFmutational status are summarized in supplementary Table
S1, available at Annals of Oncology online.
Discussion
The recent interest in primary sidedness as a potential driver of
treatment choices was raised by post hoc analyses of head-to-
head trials of first-line doublets plus either bevacizumab or an
anti-EGFR [8, 9]. Consistent results were provided in the RAS
wild-type subgroups of FIRE-3 [12], CALGB80405 [13] and
PEAK [14] studies strengthening the clear association of right-
sidedness with poor prognosis but also highlighting a new role
for primary sidedness as a predictor of benefit from anti-EGFRs.
Overall, while available data clearly identify doublets plus an
anti-EGFR as a preferred option for left-sided tumors, it
remained unclear how to improve poor survival results achieved
in right-sided primaries with doublets plus a biologic [8, 9].
Here we show that the relative benefit from FOLFOXIRI plus
bevacizumab over FOLFIRI plus bevacizumab is much more pro-
nounced in right-sided tumors independently of their RAS and
BRAF status. Though acknowledging the limited power of our
analysis, the relative over-representation of RAS mutant patients
in this study and the limited number of BRAF mutants, in all
molecular subgroups treatment effect is heterogeneous among
right- and left-sided tumors. Moreover, though recognizing
methodological limitations of cross-trial comparisons, the triplet
plus bevacizumab in molecularly unselected patients allowed
achieving remarkably better survival results than doublets plus a
biologic in the RAS wild-type subgroup of other contemporary
trials in right-sided tumors [10].
As a consequence, based on present findings, FOLFOXIRI plus
bevacizumab may be regarded as a preferred option for patients
with right-sided tumors, fit for combination, meeting clinical cri-
teria for the use of the triplet (i.e. age 18–75 years; ECOG PS 0–2
if age70 years, or 0 if age 71–75 years) [15], independently of
their molecular status. On the other side, in left-sided tumors, the
benefit from the intensification of the chemotherapy backbone
appears less pronounced, thus leading to consider doublets plus
an anti-EGFR as a preferred option in RAS and BRAF wild-type
patients, In order to validate present exploratory results, an
individual-patient data metanalysis of randomized trials compar-
ing triplet plus bevacizumab versus doublets plus bevacizumab is
currently ongoing.
Conclusion
According to this unplanned subgroup analysis of the TRIBE
study, FOLFOXIRI plus bevacizumab may be able to efficiently
counteract the intrinsic aggressiveness of right-sided mCRCs.
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